Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN).
SVB Securities, a leading investment bank serving the innovation economy, announced today that the appointment of the Federal Deposit Insurance Corporation ("FDIC") as receiver of Silicon Valley Bank will not directly impact the broker-dealer's business operations, which continue uninterrupted under the management of SVB Securities leadership team.